Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Clinical Cancer Research

• Publication date

  2016-12-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-16-1784PMID 27965309PMCID PMC5468499
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical significance of circulating CD33+CD11b+HLA-DR- myeloid cells in Stage-IV melanoma patients treated with ipilimumab

  2016cited by this paper
• MDSCs in cancer: Conceiving new prognostic and therapeutic targets.

  2016cited by this paper
• Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

  2016influential reference
• Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

  2016cited by this paper
• Clinical Significance of Circulating CD33+CD11b+HLA-DR− Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab

  2016cited by this paper
• Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

  2016cited by this paper
• Evolving synergistic combinations of targeted immunotherapies to combat cancer

  2015cited by this paper
• Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab

  2015cited by this paper
• Survival, biomarker, and toxicity analysis of nivolumab (NIVO) in patients that progressed on ipilimumab (IPI).

  2015cited by this paper
• Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.

  2015cited by this paper
• Safety and tolerability of TRAIL receptor agonists in cancer treatment

  2015cited by this paper
• Regulation of tumor metastasis by myeloid-derived suppressor cells.

  2015cited by this paper
• Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17–producing CD4+ T cells

  2015cited by this paper
• Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages.

  2015cited by this paper
• Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy

  2014cited by this paper
• Getting TRAIL back on track for cancer therapy

  2014cited by this paper
• Myeloid‐derived suppressor cell heterogeneity in human cancers

  2014cited by this paper
• ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.

  2014cited by this paper
• Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

  2014cited by this paper
• Myeloid-derived cells are key targets of tumor immunotherapy

  2014cited by this paper
• Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer

  2013cited by this paper
• A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.

  2013cited by this paper
• A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

  2013cited by this paper
• A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer.

  2013cited by this paper
• A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.

  2012cited by this paper
• First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study.

  2012cited by this paper
• Coordinated regulation of myeloid cells by tumours

  2012cited by this paper
• TRAIL receptor signaling and therapeutics

  2010cited by this paper
• Death Receptor Agonists as a Targeted Therapy for Cancer

  2010cited by this paper
• The TRAIL apoptotic pathway in cancer onset, progression and therapy

  2008cited by this paper
• Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer

  2006cited by this paper
• Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis.

  2005influential reference
• Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo

  1999cited by this paper

• Microenvironmental regulation of solid tumour resistance to CAR T cell therapy

  2025cites this paper
• Turning cold tumors into hot tumors to ignite immunotherapy

  2025cites this paper
• From numerical amplification to functional metamorphosis: the MDSC-driven therapeutic resistance in tumor.

  2025cites this paper
• Formosanin C inhibits infiltration of MDSCs by activating the STING pathway in non-small cell lung cancer.

  2025cites this paper
• DR5 CAR-T cells target melanoma and suppress MDSCs with minimal toxicity.

  2025cites this paper
• Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells

  2025cites this paper
• Targeted inhibition of Aurora kinase A promotes immune checkpoint inhibition efficacy in human papillomavirus-driven cancers

  2025cites this paper
• The heterogeneity of neutrophils in cancer and its implication for therapeutic targeting

  2025cites this paper
• The role of the tumor microenvironment and inflammatory pathways in driving drug resistance in gastric cancer: A systematic review and meta-analysis.

  2025cites this paper
• Advances in the study of death receptor 5

  2025cites this paper
• Harnessing myeloid cells in cancer

  2025cites this paper
• Myeloid cells: key players in tumor microenvironments

  2025cites this paper
• Tumor-infiltrating myeloid cells; mechanisms, functional significance, and targeting in cancer therapy

  2025cites this paper
• Monocytic myeloid-derived suppressor cells contribute to the exacerbation of bone destruction in periodontitis

  2025cites this paper
• Anti-tumor immunity mediated by engineered allogeneic stem cells exploiting TRAIL-induced cell death and FLT3L immunomodulation.

  2025cites this paper
• The important role of myeloid-derived suppressor cells: From hepatitis to liver cancer.

  2025cites this paper
• Cancer Vaccination and Immune-Based Approaches in Pancreatic Cancer

  2025cites this paper
• Transforming the "cold" tumors to "hot" tumors: strategies for immune activation.

  2025cites this paper
• Multifaceted role of myeloid-derived suppressor cells in colorectal cancer.

  2025cites this paper
• Role of myeloid-derived suppressor cells in bladder cancer and targeted therapeutic strategies.

  2025cites this paper
• MDSC: a new potential breakthrough in CAR-T therapy for solid tumors

  2024cites this paper
• Myeloid‐derived suppressor cells inhibit responses of T follicular helper cells during experimental Plasmodium yoelii infection

  2024cites this paper
• Boosting antitumor immunity in breast cancers: Potential of adjuvants, drugs, and nanocarriers

  2024cites this paper
• Targeting regulated cell death pathways in cancers for effective treatment: a comprehensive review

  2024cites this paper
• The Role of MDSCs in Digestive System Tumors and Research Progress in Targeted Therapy

  2024cites this paper
• Targeting Death Receptor 5 (DR5) for the imaging and treatment of primary bone and soft tissue tumors: an update of the literature

  2024cites this paper
• Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy

  2024cites this paper
• Myeloid-derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in colorectal cancer (Review)

  2024cites this paper
• Impact of obesity-associated myeloid-derived suppressor cells on cancer risk and progression (Review)

  2024cites this paper
• 近红外光免疫治疗策略靶向肿瘤微环境的研究进展

  2024cites this paper
• MDSCs in bone metastasis: mechanisms and therapeutic potential1.

  2024cites this paper
• Neutrophils in the tumor microenvironment: role in tumor progression and potential targeted therapeutic strategy

  2024cites this paper
• Myeloid-Derived Suppressor Cells: Therapeutic Target for Gastrointestinal Cancers

  2024influential citation
• Neutrophils at the Crossroads: Unraveling the Multifaceted Role in the Tumor Microenvironment

  2024cites this paper
• MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade

  2024cites this paper
• Carbon Ion Irradiation Activates Anti-Cancer Immunity

  2024cites this paper
• Reciprocal relationship between cancer stem cells and myeloid-derived suppressor cells: implications for tumor progression and therapeutic strategies.

  2024cites this paper
• A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance

  2024cites this paper
• Myeloid-derived suppressor cells in cancer and cancer therapy

  2024cites this paper
• Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

  2023cites this paper
• Estradiol Augments Tumor-Induced Neutrophil Production to Promote Tumor Cell Actions in Lymphangioleiomyomatosis Models.

  2023cites this paper
• Myeloid-derived suppressor cells in head and neck squamous cell carcinoma.

  2023cites this paper
• 5-Fluorouracil Suppresses Colon Tumor through Activating the p53-Fas Pathway to Sensitize Myeloid-Derived Suppressor Cells to FasL+ Cytotoxic T Lymphocyte Cytotoxicity

  2023cites this paper
• Immune Phenotypic Characterization of a TRAIL-Knockout Mouse

  2023cites this paper
• Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential

  2023cites this paper
• DIALing-up the preclinical characterization of gene-modified adoptive cellular immunotherapies

  2023cites this paper
• Hydrogel-Based Therapeutics for Pancreatic Ductal Adenocarcinoma Treatment

  2023cites this paper
• TRAIL promotes the polarization of human macrophages toward a proinflammatory M1 phenotype and is associated with increased survival in cancer patients with high tumor macrophage content

  2023cites this paper
• Counteracting Immunosenescence—Which Therapeutic Strategies Are Promising?

  2023cites this paper
• MDSCs in breast cancer: an important enabler of tumor progression and an emerging therapeutic target

  2023cites this paper
• Ferroptosis of immune cells in the tumor microenvironment.

  2023cites this paper
• Preoperative immunological plasma markers TRAIL, CSF1 and TIE2 predict survival after resection for biliary tract cancer

  2023cites this paper
• Neutrophils in the era of single-cell RNA sequencing: functions and targeted therapies in cancer

  2023cites this paper
• Combination immunotherapy for pancreatic cancer: challenges and future considerations

  2022cites this paper
• Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment.

  2022cites this paper
• Drug Resistance in Colorectal Cancer: From Mechanism to Clinic

  2022cites this paper
• Trametes robiniophila Murr Sensitizes Gastric Cancer Cells to 5-Fluorouracil by Modulating Tumor Microenvironment

  2022cites this paper
• Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets

  2022cites this paper
• Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study

  2022cites this paper
• (Im)maturity in Tumor Ecosystem

  2022cites this paper
• Mo-MDSCs are pivotal players in colorectal cancer and may be associated with tumor recurrence after surgery

  2022cites this paper
• Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data.

  2022cites this paper
• Neutrophils in pancreatic cancer: Potential therapeutic targets

  2022cites this paper
• Pharmacological modulation of myeloid-derived suppressor cells to dampen inflammation

  2022cites this paper
• Effect of crosstalk among conspirators in tumor microenvironment on niche metastasis of gastric cancer.

  2022cites this paper
• The Role of Myeloid-Derived Suppressor Cells in the Treatment of Pancreatic Cancer

  2022cites this paper
• Targeting depletion of myeloid-derived suppressor cells potentiates PD-L1 blockade efficacy in gastric and colon cancers

  2022cites this paper
• Neutrophils as potential therapeutic targets in hepatocellular carcinoma

  2022cites this paper
• The soldiers needed to be awakened: Tumor-infiltrating immune cells

  2022cites this paper
• Therapeutic strategies for gastric cancer targeting immune cells: Future directions

  2022cites this paper
• Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness

  2022cites this paper
• Phenotypic and functional heterogeneity of monocytes in health and cancer in the era of high dimensional technologies.

  2022cites this paper
• Roles of tumor-associated neutrophils in tumor metastasis and its clinical applications

  2022cites this paper
• Myeloid-derived suppressor cells in colorectal cancer: prognostic biomarkers and therapeutic targets

  2022cites this paper
• MDSCs in sepsis-induced immunosuppression and its potential therapeutic targets.

  2022cites this paper
• Cell-Cell Interactions Drive Metastasis of Circulating Tumor Microemboli.

  2022cites this paper
• Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges

  2021cites this paper
• Next-Generation Immunotherapies to Improve Anticancer Immunity

  2021cites this paper
• Myeloid‐derived suppressor cells: Bridging the gap between inflammation and pancreatic adenocarcinoma

  2021cites this paper
• Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity

  2021cites this paper
• Asah2 Represses the p53–Hmox1 Axis to Protect Myeloid-Derived Suppressor Cells from Ferroptosis

  2021cites this paper
• Novel Combinatorial Approaches to Tackle the Immunosuppressive Microenvironment of Prostate Cancer

  2021cites this paper
• Targeting the MDSCs of Tumors In Situ With Inhibitors of the MAPK Signaling Pathway to Promote Tumor Regression

  2021cites this paper
• The role of myeloid‐derived suppressor cells in gastrointestinal cancer

  2021cites this paper
• Cancer Vaccines, Adjuvants, and Delivery Systems

  2021cites this paper
• Comments on the ambiguity of selected surface markers, signaling pathways and omics profiles hampering the identification of myeloid-derived suppressor cells.

  2021cites this paper
• Combined Effects of Myeloid Cells in the Neuroblastoma Tumor Microenvironment

  2021cites this paper
• Myeloid-Derived Suppressor Cells (MDSCs) and The Immunoinflammatory Response To Injury (Mini Review).

  2021cites this paper
• Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant

  2021cites this paper
• Improving the therapeutic ratio of radiotherapy against radioresistant cancers: Leveraging on novel artificial intelligence-based approaches for drug combination discovery.

  2021cites this paper
• URRENT CONCEPT OF THE STRUCTURAL AND FUNCTIONAL PROPERTIES OF ALFA-FETOPROTEIN AND THE POSSIBILITIES OF ITS CLINICAL APPLICATION

  2021cites this paper
• CURRENT CONCEPT OF THE STRUCTURAL AND FUNCTIONAL PROPERTIES OF ALFA-FETOPROTEIN AND THE POSSIBILITIES OF ITS CLINICAL APPLICATION Gulevskyy O. K., Akhatova Yu. S

  2021cites this paper
• Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives.

  2021cites this paper
• Making Potent CAR T Cells Using Genetic Engineering and Synergistic Agents

  2021cites this paper
• Inflammation and tumor progression: signaling pathways and targeted intervention

  2021cites this paper
• Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage

  2021cites this paper
• Targeting myeloid-derived suppressor cells for cancer therapy

  2021cites this paper
• Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer

  2021cites this paper
• Myeloid-Derived Suppressor Cells: A Propitious Road to Clinic.

  2021cites this paper
• Therapeutic Values of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma: Facts and Hopes

  2021cites this paper